KEY DETAILS
A newly listed trial will test whether pairing exercise with GLP-1 therapy improves brain health and weight loss beyond the drug alone in type 2 diabetes patients.
Enrollment has wrapped on a Phase 2 study pitting BGM0504 against semaglutide in obese patients, with results still to come.
Two new GLP-1 trials were logged this week, and both speak to questions patients ask often. One looks at whether exercise adds real value on top of a GLP-1 drug. The other pits a Chinese-made GLP-1 candidate directly against semaglutide, the drug most people recognize by name. Neither trial has results yet, but the setup of each one tells you what researchers think patients want answered.
The first trial focuses on type 2 diabetes patients already taking a GLP-1 drug such as Ozempic or Mounjaro. Researchers want to know if adding a structured exercise program improves brain health and weight loss beyond what the medication delivers on its own. This matters because GLP-1 drugs are often discussed purely in terms of pounds lost, and this study asks a broader question about cognitive benefits alongside weight change. The trial is not yet recruiting, so no timeline for results exists yet. If you take a GLP-1 drug for diabetes and already exercise, this study may eventually clarify whether that habit adds measurable benefit beyond your prescription.
The second trial has just finished enrolling obese patients to compare BGM0504, a newer GLP-1 drug, directly against semaglutide in a Phase 2 study. Semaglutide is the compound behind Ozempic and Wegovy, so this comparison sets a high bar for any newcomer. Enrollment closing means the study now moves into treatment and follow-up, with results still months away. A strong showing from BGM0504 could give patients and prescribers a new option to weigh against semaglutide, particularly if cost or availability becomes a factor. For now, the trial's completion of enrollment is the only firm milestone, and the actual comparison of outcomes remains pending.
Neither trial changes anything about current prescribing today, since both are still working toward results. Patients on GLP-1 therapy for diabetes or obesity do not need to alter their treatment based on either study alone. It is reasonable to ask your prescriber whether exercise programs are recommended alongside your current medication, and to ask whether new options like BGM0504 might become relevant to your care once results are published. Watching how these two trials progress over time is a sensible way to stay informed without acting on incomplete information.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.